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A B S T R A C T
Background
Intravenous tranexamic acid reduces bleeding in surgery, however, its effect on the risk of thromboembolic events is uncertain and
an increased risk remains a theoretical concern. Because there is less systemic absorption following topical administration, the direct
application of tranexamic acid to the bleeding surface has the potential to reduce bleeding with minimal systemic effects.
Objectives
To assess the effects of the topical administration of tranexamic acid in the control of bleeding.
Search methods
We searched the Cochrane Injuries Group Specialised Register; Cochrane Central Register of Controlled Trials (CENTRAL) in The
Cochrane Library; Ovid MEDLINE®, Ovid MEDLINE® In-Process & Other Non-Indexed Citations, Ovid MEDLINE® Daily
and Ovid OLDMEDLINE®; Embase Classic + Embase (OvidSP); PubMed and ISI Web of Science (including Science Citation
Index Expanded and Social Science Citation Index (SCI-EXPANDED& CPCI-S)). We also searched online trials registers to identify
ongoing or unpublished trials. The search was run on the 31st May 2013.
Selection criteria
Randomised controlled trials comparing topical tranexamic acid with no topical tranexamic acid or placebo in bleeding patients.
Data collection and analysis
Two authors examined the titles and abstracts of citations from the electronic databases for eligibility. Two authors extracted the data
and assessed the risk of bias for each trial. Outcome measures of interest were blood loss, mortality, thromboembolic events (myocardial
infarction, stroke, deep vein thrombosis and pulmonary embolism) and receipt of a blood transfusion.
Main results
We included 29 trials involving 2612 participants. Twenty-eight trials involved patients undergoing surgery and one trial involved
patients with epistaxis (nosebleed). Tranexamic acid (TXA) reduced blood loss by 29% (pooled ratio 0.71, 95% confidence interval
(CI) 0.69 to 0.72; P < 0.0001). There was uncertainty regarding the effect on death (risk ratio (RR) 0.28, 95% CI 0.06 to 1.34; P =
0.11), myocardial infarction (RR 0.33, 95% CI 0.04 to 3.08; P = 0.33), stroke (RR 0.33, 95% CI 0.01 to 7.96; P = 0.49), deep vein
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thrombosis (RR 0.69, 95% CI 0.31 to 1.57; P = 0.38) and pulmonary embolism (RR 0.52, 95% CI 0.09 to 3.15; P = 0.48). TXA
reduced the risk of receiving a blood transfusion by a relative 45% (RR 0.55, 95% CI 0.55 to 0.46; P < 0.0001). There was substantial
statistical heterogeneity between trials for the blood loss and blood transfusion outcomes.
Authors’ conclusions
There is reliable evidence that topical application of tranexamic acid reduces bleeding and blood transfusion in surgical patients, however
the effect on the risk of thromboembolic events is uncertain. The effects of topical tranexamic acid in patients with bleeding from
non-surgical causes has yet to be reliably assessed. Further high-quality trials are warranted to resolve these uncertainties before topical
tranexamic acid can be recommended for routine use.
P L A I N L A N G U A G E S U M M A R Y
Topical treatment with a blood-clot promoting drug to reduce bleeding
Hundreds of thousands of people worldwide suffer ill health caused by severe bleeding. Tranexamic acid is a drug that helps blood to
clot and so it could help people who are bleeding. We already know that giving tranexamic acid intravenously (directly into the vein)
reduces bleeding in accident victims and in patients having operations. But some doctors don’t always give it this way because they are
worried that it might have bad side effects in certain patients, such as causing blood clots where they are not wanted. An alternative
way to give this drug is to mix it with sterile water and apply it directly to the bleeding surface (this is known as ’topical’ application).
Because less of the drug might be absorbed into the body when it is given this way, it could be less likely to have bad side effects.
This review looked at trials assessing the effects of topical tranexamic acid in patients who are bleeding. Twenty-nine trials were found;
28 involved patients bleeding during operations and one involved people with nosebleeds. When the results of these trials were gathered
together they showed that when tranexamic acid was given topically, it reduced the amount of blood that patients lost and made it less
likely that they had a blood transfusion.
The authors of this review concluded that topical tranexamic acid reduces bleeding in patients who are having an operation. But because
there are no trials, we are not sure if it also reduces bleeding from other causes, such as childbirth or bleeding from stomach ulcers.
B A C K G R O U N D
Intravenous administration of tranexamic acid reduces bleeding
during surgery. A systematic review of 129 randomised controlled
trials, including 10,488 surgical patients, showed that tranexamic
acid reduced the probability of receiving a blood transfusion by
about one third (risk ratio 0.62, 95% confidence interval 0.58 to
0.65; P < 0.001), an effect that remained large when the analysis
was restricted to high-quality trials (Ker 2012). However, the ef-
fect of tranexamic acid on the risk of thromboembolic events was
less certain. This was largely because many trials did not report
data on myocardial infarction, stroke, deep vein thrombosis and
pulmonary embolism, raising the possibility of bias from the se-
lective reporting of outcomes. Although there is no evidence that
tranexamic acid increases the risk of thromboembolic events, it
remains a theoretical concern that may dissuade some clinicians
from using this treatment in their clinical practice.
Concerns about thromboembolic events have stimulated increas-
ing interest in the topical use of tranexamic acid. Studies suggest
that plasma concentrations following the topical application of
tranexamic acid are less thanone tenth of the level after intravenous
administration (Almer 1992; McCormack 2012; Sindet-Pedersen
1987; Wong 2010). Because there is less systemic absorption, the
direct application of tranexamic acid to the bleeding surface has
the potential to reduce bleeding with minimal systemic effects.
Description of the condition
There are many clinical scenarios in which topical administration
of tranexamic acid to the bleeding surfacemight be possible. These
include epistaxis, traumatic hyphema, gastrointestinal bleeding,
surgical bleeding and uterine bleeding. All of these conditions are
common and several of them are life threatening. If the topical
applicationof tranexamic acid could safely reduce bleeding in these
conditions, this would be of substantial clinical importance.
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Description of the intervention
Tranexamic acid is a synthetic derivative of the amino acid lysine
that inhibits fibrinolysis by blocking the lysine binding site on
plasminogen (McCormack 2012). It is a competitive inhibitor of
the activation of plasminogen to plasmin and at higher concen-
trations a non-competitive inhibitor of plasmin.
How the intervention might work
Topical application of tranexamic acid has the potential to inhibit
local fibrinolysis at the site of bleeding but with minimal systemic
absorption. In this way, it could reduce bleeding and the need
for blood transfusion without systemic side effects such as throm-
boembolic events.
Why it is important to do this review
Acute severe haemorrhage is an important cause of mortality and
morbidity worldwide. Hundreds of thousands of people die as a
consequence of acute gastrointestinal and obstetric bleeding every
year (AbouZahr 2003; van der Werf 2003; van Leerdam 2008).
Furthermore, an estimated 234 million people undergo major
surgery, one million of whom die and millions more suffer com-
plications (Weiser 2008) including those caused by blood loss. If
topical administration of tranexamic acid was shown to be a safe
and effective way to reduce acute severe haemorrhage this would
be of importance to global health. Reducing bleeding would also
reduce the morbidity associated with anaemia and would reduce
the need for blood transfusion (Shander 2011). Blood is a scarce
resource and transfusion is not without risk (Goodnough 2008).
A cost-effective strategy to reduce the need for transfusion with
few or no side effects would be a major medical advance. This
review aimed to quantify the effectiveness and safety of the topi-
cal administration of tranexamic acid in reducing bleeding from a
variety of causes.
O B J E C T I V E S
To assess the effects of the topical administration of tranexamic
acid in the control of bleeding.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials.
Types of participants
People of all ages with bleeding of any severity.
Types of interventions
Topical administration of tranexamic acid versus no tranexamic
acid or placebo.
Types of outcome measures
Primary outcomes
• Blood loss (millilitres (ml); mean ± standard deviation)
• Death (n or N)
Secondary outcomes
• Myocardial infarction (n or N)
• Stroke (n or N)
• Deep vein thrombosis (n or N)
• Pulmonary embolism (n or N)
• Receipt of blood transfusion (n or N)
As assessed at the end of the follow-up period scheduled for each
trial.
We did not exclude trials based on the outcomes above.
Search methods for identification of studies
We did not restrict the searches by language or publication status.
Electronic searches
One author (DB) searched the following electronic databases:
1. Cochrane Injuries Group Specialised Register (31 May
2013);
2. Cochrane Central Register of Controlled Trials
(CENTRAL) in The Cochrane Library) (2013, Issue 5 of 12);
3. Ovid MEDLINE®, Ovid MEDLINE® In-Process &
Other Non-Indexed Citations, Ovid MEDLINE® Daily and
Ovid OLDMEDLINE® (1946 to May 2013);
4. Embase Classic + Embase (OvidSP) (1947 to 31 May
2013);
5. ISI Web of Science: Science Citation Index Expanded
(1970 to May 2013);
6. ISI Web of Science: Conference Proceedings Citation
Index-Science (1990 to May 2013).
The search strategies are reported in Appendix 1.
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Searching other resources
We searched the following online trials registers on 31 May 2013
for published and unpublished studies:
• ClinicalTrials.gov (www.clinicaltrials.gov);
• Current controlled trials (www.controlled-trials.com).
We screened reference lists of the eligible trials and any review
articles for further potentially eligible studies. We searched the
internet using the Google search engine (www.google.com) with
selected terms from the above strategy for any further unpublished
or grey literature.
Data collection and analysis
Selection of studies
Two review authors (KK and IR) examined the titles and abstracts
of the citations from the electronic databases for eligibility. We
resolved disagreements through discussion. We obtained the full
text of all potentially eligible records and two review authors (KK
and IR) assessed whether each met the predefined inclusion crite-
ria.
Data extraction and management
Two review authors (DB and KK) extracted data on the number of
trial participants, type of bleeding, dose and timing of tranexamic
acid, type of comparator and outcome data using an extraction
form developed and piloted specifically for this review.
Assessment of risk of bias in included studies
Two review authors (DB and KK) assessed the risk of bias in the
included trials using The Cochrane Collaboration’s ’Risk of bias’
tool as described in chapter 8 of the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011a). The following
domains were assessed for each trial: sequence generation, alloca-
tion concealment, blinding, incomplete outcome data, and selec-
tive outcome reporting. We completed a ’Risk of bias’ table, in-
corporating a description of the trial against each of the domains
and a judgement of the risk of bias, as follows: ’low risk’, ’high
risk’ or ’unclear risk’ of bias.
Measures of treatment effect
For the primary outcome ’blood loss’, we estimated the differ-
ence in mean blood loss between the topical tranexamic acid and
no tranexamic acid groups. We also estimated the proportional
change in blood loss with topical tranexamic acid. Specifically, we
expressed the change in blood loss with topical tranexamic acid
as a proportion of the blood loss in the control group. For the
purpose of the meta-analysis, we transformed the blood loss data
into the logarithmic scale and conducted the analysis using the
transformed values. A meta-analysis of the differences in means
using the transformed data on blood loss corresponds to a meta-
analysis of the ratio of the geometric means on the original scale.
The pooled estimates were back-transformed to give the blood loss
ratios and 95% confidence intervals on the original scale.
For the dichotomous secondary outcomes, we calculated risk ratios
and 95% confidence intervals for each trial.
Dealing with missing data
We analysed trial results on an intention-to-treat basis where the
necessary data were available. We contacted the original trial in-
vestigators to obtain missing data. For trials for which we could
not obtain missing data, we used the data available from the trial
report and conducted an available-case analysis (Higgins 2011b).
Assessment of heterogeneity
We examined the trial characteristics in terms of participants, in-
terventions and outcomes for clinical heterogeneity.We examined
statistical heterogeneity by visual inspection of forest plots, and
by the I² statistic and the Chi² test. The I² statistic describes the
percentage of total variation across studies due to heterogeneity
rather than chance. A value of 0% indicates no observed hetero-
geneity, and larger values show increasing heterogeneity; substan-
tial heterogeneity is considered to exist when I² is greater than 50%
(Deeks 2011). For theChi² test, we used a P value of less than 0.10
to indicate the presence of statistically significant heterogeneity.
Assessment of reporting biases
We investigated the presence of reporting (publication) bias using
funnel plots for outcomes for which there were 10 or more trials
included in the analysis.
Data synthesis
The effect estimates were combined using the fixed-effect model
(also known as the weighted-average method). We considered this
approach to be preferable to the random-effects model, which can
give too much weight to smaller trials that are often of poorer
methodological quality.
Subgroup analysis and investigation of heterogeneity
We conducted subgroup analyses to examine whether the effect of
topical tranexamic acid varied by the site of bleeding. We had also
planned to explore the effect by the type of topical application,
however, there were insufficient data for this analysis.
We carried out a random-effects model meta-regression to investi-
gate the association between the effect of tranexamic acid on blood
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loss and dose of tranexamic acid. The dose used in each trial was
converted into the equivalent mg per ml for analysis.
Sensitivity analysis
We conducted a sensitivity analysis to quantify the effect of tranex-
amic acid when restricted to trials with adequate allocation con-
cealment for outcomes with at least one trial contributing data to
the analysis.
Summary of findings
We presented the main results of the review in a ‘Summary of
findings’ table. We included the following outcomes:
• blood loss;
• death;
• myocardial infarction;
• stroke;
• deep vein thrombosis;
• pulmonary embolism;
• receipt of blood transfusion.
We used GRADEpro software to prepare the summary of find-
ings table. We judged the overall quality of the evidence for each
outcome as ‘high’, ‘moderate’, ‘low’ or ‘very low’ according to the
GRADE approach (Schünemann 2011). We considered the fol-
lowing:
• impact of risk of bias of individual trials;
• precision of pooled estimate;
• inconsistency or heterogeneity (clinical, methodological
and statistical);
• indirectness of evidence;
• impact of selective reporting and publication bias on effect
estimate.
R E S U L T S
Description of studies
Results of the search
The trial selection process is summarised in Figure 1. The com-
bined search strategy identified 452 records, of which 43 were
judged to be potentially eligible and the full texts were obtained.
After a full text review, 29 trials (reported in 33 articles) were in-
cluded in the review.
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Figure 1. Study flow diagram.
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Included studies
Full details of each trial are presented in the Characteristics of
included studies table; a summary is given below.
Setting
The trials were conducted in Australia, Belgium, Canada, Croatia,
Denmark, Egypt, India, Iran, Israel, Italy, Japan, Norway, Saudi
Arabia, South Korea, Sweden, Thailand, Turkey, the UK and the
USA. The publication dates of the trial reports ranged from 1979
to 2013.
Participants
Twenty-eight trials assessed the effect of topical tranexamic acid in
surgical patients. Of these trials, nine involved knee arthroplasty,
six cardiac surgery, four dental surgery, two spinal surgery, one
hip arthroplasty, one prostate resection, one pulmonary resection,
three otolaryngological surgery and one orthognathic surgery. The
single non-surgical trial assessed the effect of topical tranexamic
acid for epistaxis.
Interventions
In 23 of the 28 surgical trials, tranexamic acid was administered in
saline solution directly on to the operative site, either by pouring or
spraying into the surgical wound or as a mouthwash in the dental
surgery trials. In four of the trials involving knee arthroplasty and
the one trial of hip arthroplasty, tranexamic acid was given via an
intra-articular injection. In all of these trials tranexamic acid was
applied at the end of surgery, prior to wound closure.
In the epistaxis trial, tranexamic acid in gel form was applied to
the nasal cavity.
Twenty-five trials were placebo-controlled. In the remaining three
trials, topical tranexamic acid was compared to a no treatment
control group.
Outcomes
The amount of blood loss in millilitres measured by surgical drains
or weighing of swabs and sponges was reported in 18 trials. Three
trials estimated blood loss from the difference between pre- and
post-operative haemoglobin or haematocrit levels.
Mortality data were reported in nine trials. Myocardial infarction
data were reported in six trials, stroke data in five trials, deep vein
thrombosis in nine trials, and pulmonary embolism in eight trials.
The number of patients who received a blood transfusion was
reported in 15 trials.
Five trials did not present any data on the outcome measures of
interest to this review or reported data in a format that was un-
suitable for inclusion in the pooled analyses.
Risk of bias in included studies
The review authors’ judgements regarding each risk of bias item
for each included trial are presented in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation
One trial allocated patients into groups according to the day of
the week and one trial alternately assigned patients into groups;
both were judged to be at high risk of bias. Seventeen trials used an
adequate method of sequence generation and were judged to be at
low risk of bias; of these, nine trials referred to a random numbers
table, seven used computer-generated randomisation and one used
the drawing of lots. The remaining 10 trials were rated as unclear
due to insufficient information.
Allocation concealment
Allocations in two trials were judged to be inadequately concealed
and at high risk of bias. Six trials used a method of central allo-
cation and two trials used sequentially numbered, opaque, sealed
envelopes; all eight were considered to be adequately concealed
and at low risk of bias. The remaining 19 trials were rated as un-
clear due to insufficient information.
Blinding
Blinding of participants and personnel
Twenty trials were judged to be adequately blinded and at low risk
of performance bias. None of the trials were judged to be at high
risk of bias for this domain. The remaining nine trials were rated
as unclear due to insufficient information.
Blinding of outcome assessment: blood loss, receipt
of blood transfusion, thromboembolic events
Of the 20 trials that contributed data on blood loss, blood trans-
fusion or thromboembolic events, none were at high risk of bias,
five were rated as unclear and 11 were judged to be at low risk of
bias.
Blinding of outcome assessment: death
All nine trials that reported the number of deaths were judged to
be at low risk of bias as we judged that the outcome measurement
was unlikely to be influenced by lack of blinding.
Incomplete outcome data
Incomplete outcome data: blood loss
All of the 18 trials that reported blood loss data suitable for inclu-
sion in the meta-analysis were judged to be at low risk of attrition
bias for this outcome.
Incomplete outcome data: receipt of blood
transfusion
Of the 15 trials that reported the number of patients who received
a blood transfusion, 14 were judged to be at low risk of bias and
one at high risk of bias.
Incomplete outcome data: thromboembolic events
Of the 13 trials that reported data on thromboembolic events, 12
were judged to be at low risk of bias and one at high risk of bias.
Incomplete outcome data: death
Of the nine trials that reported the number of deaths, eight were
judged to be at low risk of bias and one at high risk of bias.
Selective reporting
One trial (Georgiadis 2013) was judged to be at low risk of bias
for selective outcome reporting as all prespecified outcomes were
reported in the final trial report. This was the only trial for which
we found a record in a clinical trial registry that was created prior
to the start of patient recruitment. The risk of bias for the re-
maining 28 trials was judged to be unclear as we had insufficient
information to permit judgement.
Effects of interventions
Blood loss
Analysis 1.1
Eighteen trials involving a total of 1651 patients reported blood
loss data suitable for inclusion in the meta-analysis.
The back-transformed pooled ratio of blood loss with topical
tranexamic acid (TXA) was 0.71 (95% confidence interval (CI)
0.69 to 0.72; P < 0.0001) indicating that topical TXA reduced
blood loss by 29%. There was substantial statistical heterogeneity
between trials (Chi² = 188.32, df = 17 (P < 0.0001); I² = 91%).
When the analysis was restricted to the five trials with adequate
allocation concealment, topical TXA reduced blood loss by 43%
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(pooled ratio 0.57, 95% CI 0.52 to 0.62; P < 0.0001). There was
substantial statistical heterogeneity between trials (Chi² = 27.79,
df = 4 (P < 0.0001); I² = 86%).
Effect by site of bleeding
There was a statistically significant reduction in blood loss in car-
diac, knee arthroplasty, spinal and otolaryngological surgery. The
point estimates were consistent with a small reduction in the topi-
cal TXA group in the trials involving thoracic surgery and orthog-
nathic surgery although they were imprecise and not statistically
significant.
• Cardiac surgery, 7 trials (n = 511): pooled ratio 0.63 (95%
CI 0.61 to 0.66; P < 0.0001); Chi² = 21.76, df = 6 (P = 0.001);
I² = 72%.
• Knee arthroplasty, 5 trials (n = 427): pooled ratio 0.57
(95% CI 0.53 to 0.62; P < 0.0001); Chi² = 33.89, df = 4 (P <
0.0001); I² = 88%.
• Orthognathic surgery, 1 trial (n = 40): ratio 0.93 (95% CI
0.73 to 1.20; P = 0.60).
• Otolaryngological surgery, 2 trials (n = 456): pooled ratio
0.74 (95% CI 0.73 to 0.76; P < 0.0001); Chi² = 1.93, df = 1 (P
= 0.16); I² = 48%.
• Spinal surgery, 2 trials (n = 130): pooled ratio 0.50 (95%
CI 0.43 to 0.58; P < 0.0001); Chi² = 0.39, df = 1 (P = 0.53); I² =
0%.
• Thoracic surgery, 1 trial (n = 87): ratio 0.95 (95% CI 0.86
to 1.05; P = 0.35).
Test for subgroup differences: Chi² = 130.34, df = 5 (P < 0.0001);
I² = 96.2%.
Effect by dose
The concentrationofTXAused in the 18 trials ranged from0.7mg
to 100 mg/ml of saline solution. The result of the meta-regression
analysis suggested that the effect of TXA on blood loss did not
vary over this range (coefficient = 1.0003; P = 0.84).
Estimated blood loss
Analysis 1.2
Three trials estimated the amount of blood loss based on the dif-
ference between pre- and post-operative haemoglobin or haemat-
ocrit. Data from these trials were not suitable for inclusion in the
pooled analysis and were considered separately. All three trials ob-
served a statistically significant difference in the amount of blood
loss with topical TXA.
Mortality
Analysis 1.3
Nine trials involving a total of 894 participants reported mortal-
ity data. No deaths occurred in seven trials, therefore the pooled
analysis was based on data from two trials involving a total of nine
deaths among 293 participants.
There was no difference in the risk of death between the topical
TXA and control groups, the pooled risk ratio (RR)was 0.28 (95%
CI 0.06 to 1.34; P = 0.11). There was no statistical heterogeneity
between trials (Chi² = 0.03, df = 1 (P = 0.86); I² = 0%).
When the analysis was restricted to the one trial with adequate
allocation concealment, there was no difference in the risk of death
between the groups (RR 0.33, 95% CI 0.03 to 3.12; P = 0.33).
Thromboembolic events
Myocardial infarction
Analysis 1.4
Six trials involving a total of 362 participants reported data on
myocardial infarction. It was reported that no patients suffered
myocardial infarction in four trials, therefore the pooled analysis
was based on data from two trials involving a total of two events
among 127 participants.
There was no difference in the risk of myocardial infarction be-
tween the topical TXA and control groups, the pooled RR was
0.33 (95% CI 0.04 to 3.08; P = 0.33). There was no statistical
heterogeneity between trials (Chi² = 0.00, df = 1 (P = 0.99); I² =
0%).
There were no cases of myocardial infarction in the two trials with
adequate allocation concealment.
Stroke
Analysis 1.5
Five trials involving a total of 441 participants reported data on
stroke. It was reported that no patients suffered a stroke in four
trials, thus the analysis was based on data from one trial (with
adequate allocation concealment) involving a total of one event
among 157 participants.
There was no difference in the risk of stroke between the topical
TXA and control groups, the RR was 0.33 (95% CI 0.01 to 7.96;
P = 0.49).
Deep vein thrombosis
Analysis 1.6
Nine trials involving a total of 789 participants reported data on
deep vein thrombosis. It was reported that no patients suffered a
deep vein thrombosis in five trials, therefore the analysis was based
on data from four trials involving a total of 21 events among 457
participants.
There was no difference in the risk of deep vein thrombosis be-
tween the topical TXA and control groups, the RR was 0.69 (95%
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CI 0.31 to 1.57; P = 0.38). There was no statistically significant
heterogeneity between trials (Chi² = 3.41, df = 3 (P = 0.33); I² =
12%).
When the analysis was restricted to the three trials with adequate
allocation concealment, there was no difference in the risk of death
between the groups (pooled RR 0.81, 95% CI 0.34 to 1.92; P =
0.63). There was no statistically significant heterogeneity between
trials (Chi² = 2.81, df = 2 (P = 0.25); I² = 29%).
Pulmonary embolism
Analysis 1.7
Eight trials involving a total of 741 participants reported data on
pulmonary embolism. It was reported that no patients suffered a
pulmonary embolism in six trials, therefore the analysis was based
on data from two trials (both with adequate allocation conceal-
ment) involving a total of five events among 200 participants.
There was no difference in the risk of pulmonary embolism be-
tween the topical TXA and control groups, the RR was 0.52 (95%
CI 0.09 to 3.15; P = 0.48). There was no statistically significant
heterogeneity between trials (Chi² = 0.00, df = 1 (P = 0.97); I² =
0%).
Blood transfusion
Analysis 1.8
Fifteen trials involving a total of 1623 participants reported data
on receipt of blood transfusion. It was reported that no patients
received a blood transfusion in one trial, therefore the analysis was
based on data from 14 trials involving a total of 311 events among
1523 participants.
Topical TXA reduced the risk of receiving a blood transfusion
by 45% (pooled RR 0.55, 95% CI 0.46 to 0.65; P < 0.0001).
There was substantial statistical heterogeneity between trials (Chi²
= 54.48, df = 13 (P < 0.0001); I² = 76%).
When the analysis was restricted to the seven trials with adequate
allocation concealment, topical TXA reduced the risk of receiving
a blood transfusion by 33% (pooled RR 0.67, 95% CI 0.54 to
0.84; P = 0.001). There was substantial statistical heterogeneity
between trials (Chi² = 25.68, df = 6 (P = 0.0003); I² = 77%).
Reporting bias
Therewere sufficient data to produce funnel plots for the blood loss
and blood transfusion outcomes. There was no clear asymmetry
in the funnel plot for blood loss (Figure 3). However, inspection
of the funnel plot for blood transfusion suggested the presence of
small study effects favouring topical TXA (Figure 4).
Figure 3. Funnel plot of comparison: 1 Topical TXA versus control, outcome: 1.1 Blood loss.
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Figure 4. Funnel plot of comparison: 1 Topical TXA versus control, outcome: 1.8 Blood transfusion.
Summary of findings and quality of the evidence
The summary of findings and GRADE evidence profile for the
use of topical TXA for surgical bleeding are presented in Figure 5.
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Figure 5. Summary of findings table and GRADE evidence profile: Should topical TXA be used for the
reduction of surgical bleeding?
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D I S C U S S I O N
Summary of main results
There is reliable evidence that the topical application of tranex-
amic acid reduces bleeding in surgical patients. Data pooled across
trials conducted in a range of surgical procedures suggest that the
topical application of tranexamic acid reduces surgical blood loss
by about one third. However, the magnitude of the effect varies
when stratified by the type of surgery. There is no evidence for a
dose-response relationship with blood loss over the range of doses
assessed by the trials (0.7 to 100 mg/ml). Topical tranexamic acid
also reduces the risk of receiving a blood transfusion in surgical
patients, however, the effect on the risk of thromboembolic events
in this patient group is uncertain. The effects of topical tranexamic
acid in patients with bleeding from non-surgical causes have not
been assessed by clinical trials and are uncertain.
Overall completeness and applicability of
evidence
The pooled analyses which inform the results of this systematic
review are based on data from trials conducted in surgery. We
found only one trial that had been conducted in a non-surgical
setting, although the reported data were not suitable for inclusion
in the quantitative analyses. We cannot assume that the same ef-
fect would be observed in other bleeding conditions such as gas-
trointestinal or obstetric bleeding. However, the similar under-
lying haemostatic response and the observed beneficial effect in
surgery raise the possibility that topical tranexamic acid might also
be effective in other bleeding conditions and warrants further in-
vestigation.
Quality of the evidence
Most of the trials were judged to be at low or unclear risk of bias.
When the analysis was restricted to trials with adequate allocation
concealment the favourable effect of topical tranexamic acid on
both the amount of blood loss and risk of blood transfusion re-
mained large and statistically significant. Systematic error resulting
from methodological limitations of the included trials is therefore
unlikely to fully explain the observed effect.
None of the trials were adequately powered to detect the impact on
the clinically important outcomes of death and thromboembolic
events, therefore the pooled estimates are imprecise and compat-
ible with an increase or decrease in risk. Furthermore, less than
a third of the included trials reported data on these outcomes,
raising the possibility of selective outcome reporting. The effect
of such bias on the results of this review is open to question.
Potential biases in the review process
The possibility of publication bias should be considered as a po-
tential threat to the validity of the findings of this systematic re-
view. In light of our extensive and sensitive searching, we believe
that it is unlikely that any published trials were missed, although
it is possible that we missed unpublished trials. Indeed, the ob-
served asymmetry in the funnel plot for blood transfusion could
be explained by publication bias. If there are many unpublished
trials showing little or no effect of topical tranexamic acid on blood
transfusion, then this meta-analysis may have overestimated the
treatment effect. Although some degree of overestimation for this
outcome is likely, it seems improbable that publication bias could
account for all of the observed effect.
There was substantial statistical heterogeneity for the blood loss
and blood transfusion outcomes, which was not explained by type
of surgery, dose or adequacy of allocation concealment.Differences
in the methods of measuring blood loss and aspects of method-
ological quality between trials may have contributed to the het-
erogeneity. It is important to note that the heterogeneity describes
variation in the magnitude not the direction of the effect, with
all point estimates for blood loss consistent with a reduction with
topical tranexamic acid within subgroups.
Agreements and disagreements with other
studies or reviews
Our results are consistent with those from other systematic reviews
and randomised trials assessing the effect of tranexamic acid. A
systematic review of randomised trials assessing the effects of in-
travenous tranexamic acid in patients undergoing surgery found
that it reduced blood loss and the risk of receiving a blood trans-
fusion although the effect on risk of death and thromboembolic
events was uncertain (Ker 2012; Ker 2013). The CRASH-2 trial
that involved 20,211 bleeding trauma patients found that early
administration of intravenous tranexamic acid reduced the risk of
death due to bleeding by about a third, with no increase in throm-
boembolic events (CRASH-2 Collaborators 2011).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The topical application of tranexamic acid reduces bleeding and
blood transfusion in patients undergoing surgery. As there is less
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systemic absorption following topical administration, clinicians
reluctant to administer tranexamic acid intravenously to high-risk
surgical patients, out of concern for increased risk of thromboem-
bolic events, may consider topical application as an alternative.
Implications for research
There is a need for high-quality randomised controlled trials to
resolve the uncertainties surrounding the effects of topical appli-
cation of tranexamic acid on risk of thromboembolic events and
to assess its effects in patients with bleeding from non-surgical
causes.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abdullah 2012
Methods Randomised placebo-controlled trial
Setting: not described
Participants 52 patients undergoing transurethral resection of the prostate
• Topical TXA group (n=NR): all male, age not reported
• Control group (n=NR): all male, age not reported
Interventions • Topical TXA group: 500mg in 1000ml saline irrigation fluid
• Control group: placebo (saline)
Outcomes Prostatic weight
Duration of resection
Haemoglobin level
Notes Conference abstract
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported
Allocation concealment (selection bias) Unclear risk No information reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No data on this outcome reported
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Unclear risk No data on this outcome reported
Blinding of outcome assessment (detection
bias)
Death
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Blood loss
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Unclear risk No data on this outcome reported
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Abdullah 2012 (Continued)
Incomplete outcome data (attrition bias)
Thromboembolic events
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Death
Unclear risk No data on this outcome reported
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Abul-Azm 2006
Methods Randomised placebo-controlled trial
Setting: unclear
Participants 100 patients undergoing elective open heart surgery
• Topical TXA group (n=50): M/F=24/26; median age (range)=57 (43-73)
• Control group (n=50): M/F=28/22; median age (range)=55 (44-78)
Interventions • Topical TXA group: 2g in 100ml saline poured into pericardial cavity
• Control group: placebo (saline)
Outcomes Blood loss (drainage of mediastinal blood)
Death
Hospital stay
Re-exploration
Use of blood product for transfusion
Haematology and coagulation variables
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Unclear risk No information reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported that “all anaesthesiologists and
surgeons were blinded to group allocation”
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Unclear risk Reported that “all anaesthesiologists and
surgeons were blinded to group allocation”
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Abul-Azm 2006 (Continued)
Blinding of outcome assessment (detection
bias)
Death
Unclear risk Reported that “all anaesthesiologists and
surgeons were blinded to group allocation”
Incomplete outcome data (attrition bias)
Blood loss
Low risk No exclusions described
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Low risk No exclusions described
Incomplete outcome data (attrition bias)
Thromboembolic events
Low risk No exclusions described
Incomplete outcome data (attrition bias)
Death
Low risk No exclusions described
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Albirmawy 2013
Methods Randomised placebo-controlled trial
Setting: Egypt
Participants 400 children undergoing primary isolated adenoidectomy
• Topical TXA group (n=200): M/F=131/69; mean age (sd)=5.6 (2.5)
• Control group (n=200): M/F=119/81; mean age (sd)=4.9 (1.8)
Interventions • Topical TXA group: 1g in 10ml saline poured into nasopharynx
• Control group: placebo (saline)
Outcomes Blood loss (intra-operative, suctioned blood)
Frequency of post-operative bleeding
Use of blood product for transfusion
Haematology and coagulation variables
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers table
Allocation concealment (selection bias) Unclear risk “The solutions were prepared by one of the
co-authors in two identical bottles and de-
livered to the operative theatre”
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Albirmawy 2013 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Neither the surgeon, anaesthetist or the
scrub nurse knew the composition of the
solution administered
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Low risk Neither the surgeon, anaesthetist or the
scrub nurse knew the composition of the
solution administered
Blinding of outcome assessment (detection
bias)
Death
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Blood loss
Low risk No exclusions described
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Low risk No exclusions described
Incomplete outcome data (attrition bias)
Thromboembolic events
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Death
Unclear risk No data on this outcome reported
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Alshryda 2013
Methods Randomised placebo-controlled trial
Setting: UK
Participants 157 patients undergoing knee arthroplasty
• Topical TXA group (n=79): M/F=30/49; mean age (sd)=65.5 (9.6)
• Control group (n=78): M/F=44/34; mean age (sd)=67.1 (10.2)
Interventions • Topical TXA group: 1g/50ml saline sprayed into the wound at the end of the
operation
• Control group: placebo (saline)
Outcomes Blood loss
Blood transfusion
Thromboembolic events
Haematology variables
Joint function
Length of stay
Quality of life assessment
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Alshryda 2013 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Low risk Central allocation (web-based)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Surgeons and their teammembers and pa-
tients remained blinded to the allocation.”
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Low risk “Surgeons and their teammembers and pa-
tients remained blinded to the allocation.”
Blinding of outcome assessment (detection
bias)
Death
Low risk “Surgeons and their teammembers and pa-
tients remained blinded to the allocation.”
Incomplete outcome data (attrition bias)
Blood loss
Low risk No exclusions and intention-to-treat anal-
ysis
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Low risk No exclusions and intention-to-treat anal-
ysis
Incomplete outcome data (attrition bias)
Thromboembolic events
Low risk No exclusions and intention-to-treat anal-
ysis
Incomplete outcome data (attrition bias)
Death
Low risk No exclusions and intention-to-treat anal-
ysis
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Athanasiadis 2007
Methods Randomised placebo-controlled trial
Setting: Australia
Participants 30 patients undergoing sinus surgery: M/F=19/11; median age (range)=51 (19-79)
Each patient received both trial treatments: topical tranexamic acid was applied to one
side of the nasal cavity and placebo to the other
• Topical TXA group 1 versus control (n=10)
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Athanasiadis 2007 (Continued)
• Topical TXA group 2 versus control (n=10)
[*third group of 10 patients received EACA versus control, not included in this review]
Interventions • Topical TXA group 1: 100mg sprayed into nasal cavity
• Topical TXA group 2: 1g sprayed into nasal cavity
• Control group: placebo (saline)
Outcomes Surgical site grade of bleeding
Post-operative epistaxis
Adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Unclear risk “Sealed envelope”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The surgical team and the independent
observer thus were blinded as to which
agent the patient was receiving...”
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Unclear risk No data on this outcome reported
Blinding of outcome assessment (detection
bias)
Death
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Blood loss
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Thromboembolic events
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Death
Unclear risk No data on this outcome reported
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
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Baric 2007
Methods Randomised controlled trial
Setting: Croatia
Participants 300* patients undergoing elective cardiac surgery
• Topical TXA group (n=97): M/F=77/20; mean age (sd)=61.2 (10.7)
• Control group (n=96): M/F=70/26; mean age (sd)=61.2 (10.3)
[*third group of 100 patients received aprotinin, not included in this review]
Interventions • Topical TXA group: 2.5g in 250ml saline poured into pericardial cavity
• Control group: placebo (saline)
Outcomes Blood loss
Blood product transfusion
Death
Haematology and coagulation variables
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers table
Allocation concealment (selection bias) Low risk “The independent pharmacologist in the
hospital pharmacy prepared coded solu-
tions with the study drugs and was not
directly involved in the clinical treatment
of randomised patients...Identical bottles
marked with a study number were deliv-
ered to the operating theatres. Codes were
disclosed at the end of the study.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Both the operation theatre staff and that
of the intensive care unit were blinded re-
garding the study drug and codes were dis-
closed at the end of the study.”
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Low risk “Both the operation theatre staff and that
of the intensive care unit were blinded re-
garding the study drug and codes were dis-
closed at the end of the study.”
Blinding of outcome assessment (detection
bias)
Death
Low risk “Both the operation theatre staff and that
of the intensive care unit were blinded re-
garding the study drug and codes were dis-
closed at the end of the study.”
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Baric 2007 (Continued)
Incomplete outcome data (attrition bias)
Blood loss
Low risk “Six patients were withdrawn from the
study due to postoperative reopening for
bleeding where an evident surgical source
for bleeding was discovered. One patient
dropped-out from the study due to the
technical mistake.”
Missing outcomedata balanced innumbers
across groups.
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Low risk “Six patients were withdrawn from the
study due to postoperative reopening for
bleeding where an evident surgical source
for bleeding was discovered. One patient
dropped-out from the study due to the
technical mistake.”
Missing outcomedata balanced innumbers
across groups.
Incomplete outcome data (attrition bias)
Thromboembolic events
Low risk “Six patients were withdrawn from the
study due to postoperative reopening for
bleeding where an evident surgical source
for bleeding was discovered. One patient
dropped-out from the study due to the
technical mistake.”
Missing outcomedata balanced innumbers
across groups.
Incomplete outcome data (attrition bias)
Death
Low risk “Six patients were withdrawn from the
study due to postoperative reopening for
bleeding where an evident surgical source
for bleeding was discovered. One patient
dropped-out from the study due to the
technical mistake.”
Missing outcomedata balanced innumbers
across groups.
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Blinder 1999
Methods Randomised placebo-controlled trial
Setting: Israel
Participants 150* patients undergoing dental extraction
• Topical TXA group (n=50): M/F=33/17; age range=35-79
• Control group (n=50): M/F=35/15; age range=40-86
[*third group of 50 patients received fibrin glue, not included in this review]
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Blinder 1999 (Continued)
Interventions • Topical TXA group: 500mg as mouthwash, rinsed for 2 minutes 4 times a day for
4 day post-operatively
• Control group: no mouthwash containing TXA
Outcomes Post-operative bleeding
Anti-coagulant activity
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Assigned according to day of week
Allocation concealment (selection bias) High risk Assigned according today ofweek therefore
not concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No data on this outcome reported
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Unclear risk No data on this outcome reported
Blinding of outcome assessment (detection
bias)
Death
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Blood loss
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Thromboembolic events
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Death
Unclear risk No data on this outcome reported
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
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Canata 2012
Methods Randomised controlled trial
Participants 96* patients undergoing knee arthroplasty; mean age (range)=70 (47-83)
• Topical TXA group (n=32): M/F=11/21
• Control group (n=32): M/F=7/8
[*third group of 32 patients received a mixture of ropivacaine, clonidine, ketorolac and
norepinephrine, not included in this review]
Interventions • Topical TXA group: received “infiltration of tranexamic acid” (no other details
presented)
• Control group: “no infiltration was performed”
Outcomes Blood loss*
Receipt of blood transfusion*
KOOS outcome score
Haemoglobin
[*insufficient data reported to allow inclusion in meta-analysis]
Notes Conference abstract only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported
Allocation concealment (selection bias) Unclear risk No information reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information reported
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Unclear risk No data on this outcome reported
Blinding of outcome assessment (detection
bias)
Death
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Blood loss
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Unclear risk No data on this outcome reported
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Canata 2012 (Continued)
Incomplete outcome data (attrition bias)
Thromboembolic events
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Death
Unclear risk No data on this outcome reported
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement
De Bonis 2000
Methods Randomised placebo-controlled trial
Setting: Italy
Participants 40 patients undergoing primary coronary artery surgery
• Topical TXA group (n=20): M/F=17/3; mean age (sd)=62 (7)
• Control group (n=20): M/F=18/2; mean age (sd)=60 (6)
Interventions • Topical TXA group: 1g in 100ml saline
• Control group: placebo (saline)
Outcomes Blood loss
Receipt of blood products
Myocardial infarction
Haematology and coagulation variables
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers table
Allocation concealment (selection bias) Unclear risk “Sealed envelopes were prepared and left in
a box in the operating theatre. On the day
of surgery, the theatre nurse selected the
next card from the box and this determined
which solution was to be used.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Neither the surgeons, anaesthetists, scrub
nurses nor perfusionists knew the compo-
sition of the solution administered.”
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Low risk “Neither the surgeons, anaesthetists, scrub
nurses nor perfusionists knew the compo-
sition of the solution administered.”
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De Bonis 2000 (Continued)
Blinding of outcome assessment (detection
bias)
Death
Low risk “Neither the surgeons, anaesthetists, scrub
nurses nor perfusionists knew the compo-
sition of the solution administered.”
Incomplete outcome data (attrition bias)
Blood loss
Low risk No exclusions reported
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Low risk No exclusions reported
Incomplete outcome data (attrition bias)
Thromboembolic events
Low risk No exclusions reported
Incomplete outcome data (attrition bias)
Death
Low risk No exclusions reported
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Dell’Amore 2012
Methods Randomised controlled trial
Setting: Italy
Participants 89 patients undergoing pulmonary resection
• Topical TXA group (n=45): M/F=29/16; mean age (sd)=65.8 (6.4)
• Control group (n=44): M/F=31/13; mean age (sd)=67.7 (6.4)
Interventions • Topical TXA group: 5g 100ml of saline solution poured into chest at end of
resection
• Control group: placebo (saline)
Outcomes Blood loss
Receipt of blood products
Thromboembolic events
Haematology and coagulation variables
Notes Some additional unpublished data provided by trial author
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers table
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
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Dell’Amore 2012 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The operation room staff, the ward staff
and the intensive care unit staff were all
blinded regarding the study solution”
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Low risk “The operation room staff, the ward staff
and the intensive care unit staff were all
blinded regarding the study solution”
Blinding of outcome assessment (detection
bias)
Death
Low risk “The operation room staff, the ward staff
and the intensive care unit staff were all
blinded regarding the study solution”
Incomplete outcome data (attrition bias)
Blood loss
Low risk 2 patients (one from each group) were
excluded because of major post-operative
bleeding with surgical source
Missing outcome data balanced in numbers
across groups
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Low risk 2 patients (one from each group) were
excluded because of major post-operative
bleeding with surgical source
Missing outcome data balanced in numbers
across groups
Incomplete outcome data (attrition bias)
Thromboembolic events
Low risk 2 patients (one from each group) were
excluded because of major post-operative
bleeding with surgical source
Missing outcome data balanced in numbers
across groups
Incomplete outcome data (attrition bias)
Death
Low risk 2 patients (one from each group) were
excluded because of major post-operative
bleeding with surgical source
Missing outcome data balanced in numbers
across groups
Selective reporting (reporting bias) Unclear risk Insufficient information reported to permit
judgement
Fawzy 2009
Methods Randomised placebo-controlled trial
Setting: Saudi Arabia
Participants 38 patients undergoing isolated coronary artery bypass grafting
• Topical TXA group (n=19): M/F=18/1; mean age (sd)=55 (11)
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Fawzy 2009 (Continued)
• Control group (n=19): M/F=18/1; mean age (sd)=60 (7)
Interventions • Topical TXA group: 1g 100ml of saline solution poured into pericardial and
mediastinal cavities
• Control group: placebo (saline)
Outcomes Blood loss
Blood products transfused
Death
Thromboembolic events
Re-exploration
Haematology and coagulation variables
Notes Additional unpublished data obtained from trial author
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers table
Allocation concealment (selection bias) Low risk “Research pharmacist who prepared the
two solutions in two identical bottles de-
livered to the operating theatre.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Neither the surgeons, anaesthetists, scrub
nurses nor perfusionists knew the compo-
sition of the solution administered.”
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Low risk “Neither the surgeons, anaesthetists, scrub
nurses nor perfusionists knew the compo-
sition of the solution administered.”
Blinding of outcome assessment (detection
bias)
Death
Low risk “Neither the surgeons, anaesthetists, scrub
nurses nor perfusionists knew the compo-
sition of the solution administered.”
Incomplete outcome data (attrition bias)
Blood loss
Low risk No exclusions
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Low risk No exclusions
Incomplete outcome data (attrition bias)
Thromboembolic events
Low risk No exclusions
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Fawzy 2009 (Continued)
Incomplete outcome data (attrition bias)
Death
Low risk No exclusions
Selective reporting (reporting bias) Unclear risk Insufficient information reported to permit
judgement
Georgiadis 2013
Methods Randomised placebo-controlled trial
Setting: USA
Participants 101 patients undergoing total knee arthroplasty
• Topical TXA group (n=50): M/F=19/31; mean (sd) age=67.0 (9.0)
• Control group (n=51): M/F=12/39; mean (sd) age=64.5 (8.2)
Interventions • Topical TXA group: 2g in 75ml of saline solution applied to the wound bed after
component placement
• Control group: placebo (saline)
Outcomes Blood loss
Blood transfusion
Venous thromboembolism rates
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Pharmacy-controlled
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Low risk Described as double-blind
Blinding of outcome assessment (detection
bias)
Death
Unclear risk No data on this outcome reported
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Georgiadis 2013 (Continued)
Incomplete outcome data (attrition bias)
Blood loss
Low risk No exclusions described
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Low risk No exclusions described
Incomplete outcome data (attrition bias)
Thromboembolic events
Low risk No exclusions described
Incomplete outcome data (attrition bias)
Death
Unclear risk No data on this outcome reported
Selective reporting (reporting bias) Low risk Registered on ClinicalTrials.gov prior to
trial completion - prespecified outcomes re-
ported in final trial report
Gersel-Pedersen 1979
Methods Randomised placebo-controlled trial
Setting: Denmark
Participants 120 patients undergoing bilateral molar extraction (240 extractions); mean age (range)
=23.2 (14-58)
• Topical TXA group (n=120): M/F=NR
• Control group (n=120): M/F=NR
Interventions • Topical TXA group: 40mg - before closure of wound 4 triangular cones were
applied in each socket
• Control group: placebo (saline)
Outcomes Development of alveolitis sicca dolorosa
Post-operative pain, swelling
Bleeding
Re-operation
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Information not reported
Allocation concealment (selection bias) Unclear risk Information not reported
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Gersel-Pedersen 1979 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial described as double-blind
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Unclear risk No data on this outcome reported
Blinding of outcome assessment (detection
bias)
Death
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Blood loss
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Thromboembolic events
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Death
Unclear risk No data on this outcome reported
Selective reporting (reporting bias) Unclear risk Insufficient information reported to permit
judgement
Ishida 2011
Methods Randomised placebo-controlled trial
Setting: Japan
Participants 100 patients undergoing knee arthroplasty
• Topical TXA group (n=50): M/F=6/44; mean age (sd)=73.3 (5.0)
• Control group (n=50): M/F=6/44; mean age (sd)=73.5 (6.1)
Interventions • Topical TXA group: 2000mg/20ml injected into knee joint immediately after
wound closure through a drain
• Control group: placebo (saline)
Outcomes Blood loss
Receipt of blood products
Swelling of knee joint
Haematology and coagulation variables
Notes
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Ishida 2011 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “patients were alternately assigned”
Allocation concealment (selection bias) High risk “patients were alternately assigned”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information reported
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Low risk “Measurements were performed twice each
day in each patient by two authors blinded
to clinical information”
Blinding of outcome assessment (detection
bias)
Death
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Blood loss
Low risk No exclusions described
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Low risk No exclusions described
Incomplete outcome data (attrition bias)
Thromboembolic events
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Death
Unclear risk No data on this outcome reported
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Jabalameli 2006
Methods Randomised controlled trial.
Setting: Iran
Participants 56 patients undergoing sinus surgery; M/F=38/18; age range=18-55
• Topical TXA group (n=26)
• Control group (n=30)
Interventions • Topical TXA group: 1000mg in 20ml saline “administered topically”
• Control group: placebo (saline)
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Jabalameli 2006 (Continued)
Outcomes Intra-operative bleeding
Haemodynamic endpoints
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported
Allocation concealment (selection bias) Unclear risk No information reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information reported
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Unclear risk No information reported
Blinding of outcome assessment (detection
bias)
Death
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Blood loss
Low risk No exclusions reported
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Thromboembolic events
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Death
Unclear risk No data on this outcome reported
Selective reporting (reporting bias) Unclear risk Insufficient information reported to permit
judgement
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Kaewpradub 2011
Methods Randomised placebo-controlled trial
Setting: Thailand
Participants 40 patients undergoing bimaxillary osteotomy
• Topical TXA group (n=20); M/F=5/15; mean age (sd)=26.25 (5.01)
• Control group (n=20); M/F=11/9; mean age (sd)=25.55 (7.11)
Interventions • Topical TXA group: 500mg (10ml) in saline for tissue irrigation and cooling of
the instrument
• Control group: placebo (saline)
Outcomes Blood loss
Volume of blood transfused
Operation time
Haematocrit levels
Hypotensive time
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “patients were assigned randomly to 2
groups by drawing lots”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial is described as double-blind and re-
ported that “...anaesthesiologist and a sur-
gical team who were blinded to the type of
irrigation fluid”
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Low risk Trial is described as double-blind and re-
ported that “...anaesthesiologist and a sur-
gical team who were blinded to the type of
irrigation fluid”
Blinding of outcome assessment (detection
bias)
Death
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Blood loss
Low risk No exclusions reported
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Unclear risk No data on this outcome reported
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Kaewpradub 2011 (Continued)
Incomplete outcome data (attrition bias)
Thromboembolic events
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Death
Unclear risk No data on this outcome reported
Selective reporting (reporting bias) Unclear risk Insufficient information reported to permit
judgement
Krohn 2002
Methods Randomised placebo-controlled trial
Setting: Norway
Participants 30 patients undergoing spinal surgery; median age (IQR)=47 (24-70)
• Topical TXA group (n=16); M/F=7/9
• Control group (n=14); M/F=5/9
Interventions • Topical TXA group: 500mg in 50ml saline, irrigation of wound at end of
operation for 2-5 minutes
• Control group: placebo (saline)
Outcomes Blood loss
Blood transfusion
Plasmin and D-dimer concentrations
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “...according to the randomisation table.”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “surgeons and the personnel in the postop-
erative ward were unaware of who received
tranexamic acid and who did not”
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Low risk “surgeons and the personnel in the postop-
erative ward were unaware of who received
tranexamic acid and who did not”
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Krohn 2002 (Continued)
Blinding of outcome assessment (detection
bias)
Death
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Blood loss
Low risk No exclusions reported
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Low risk No exclusions reported
Incomplete outcome data (attrition bias)
Thromboembolic events
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Death
Unclear risk No data on this outcome reported
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Kurt 2011
Methods Randomised controlled trial
Setting: Turkey
Participants 100 patients undergoing cardiac surgery
• Topical TXA group (n=20); M/F=17/3; mean age (sd)=56.8 (10.7)
• Control group (n=20); M/F=16/4; mean age (sd)=60.2 (10.6)
Interventions • Topical TXA group: 1mg/kg in 100ml poured into mediastinum
• Control group: no TXA
Outcomes Blood loss
Amount of blood transfused
Haematology and coagulation variables
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
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Kurt 2011 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
Death
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Blood loss
Low risk No exclusions reported
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Thromboembolic events
Low risk No exclusions reported
Incomplete outcome data (attrition bias)
Death
Unclear risk No data on this outcome reported
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Nouraei 2013
Methods Randomised placebo-controlled trial
Setting: Iran
Participants 80 patients undergoing cardiac surgery
• Topical TXA group (n=40); M/F=29/11; mean age (sd)=60 (9.64)
• Control group (n=40); M/F=25/15; mean age (sd)=59.64 (10.03)
Interventions • Topical TXA group: 2g/kg in 500ml poured into pericardial cavity prior to closure
• Control group: placebo
Outcomes Blood loss (mediastinal drainage)
Blood transfusion
Haematology and coagulation variables
Mortality
Complications (myocardial infarction, stroke, deep vein thrombosis, pulmonary em-
bolism, seizures, re-exploration, renal failure)
Notes
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Nouraei 2013 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer made random number table”
Allocation concealment (selection bias) Unclear risk Reported that a ’third party’ was used. No
other information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported: “This was double-blind study,
and with the exception of one nurse who
prepared the solution, none of the patients,
doctors, nurses or laboratory staff were
aware of the type of therapy”
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Low risk Reported: “This was double-blind study,
and with the exception of one nurse who
prepared the solution, none of the patients,
doctors, nurses or laboratory staff were
aware of the type of therapy”
Blinding of outcome assessment (detection
bias)
Death
Low risk Reported: “This was double-blind study,
and with the exception of one nurse who
prepared the solution, none of the patients,
doctors, nurses or laboratory staff were
aware of the type of therapy”
Incomplete outcome data (attrition bias)
Blood loss
Low risk Reported: “This was double-blind study,
and with the exception of one nurse who
prepared the solution, none of the patients,
doctors, nurses or laboratory staff were
aware of the type of therapy”
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Low risk Reported: “This was double-blind study,
and with the exception of one nurse who
prepared the solution, none of the patients,
doctors, nurses or laboratory staff were
aware of the type of therapy”
Incomplete outcome data (attrition bias)
Thromboembolic events
Low risk Reported: “This was double-blind study,
and with the exception of one nurse who
prepared the solution, none of the patients,
doctors, nurses or laboratory staff were
aware of the type of therapy”
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Nouraei 2013 (Continued)
Incomplete outcome data (attrition bias)
Death
Low risk Reported: “This was double-blind study,
and with the exception of one nurse who
prepared the solution, none of the patients,
doctors, nurses or laboratory staff were
aware of the type of therapy”
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment. Retrospective registration on trial
registry
Ramstrom 1993
Methods Randomised placebo-controlled trial
Setting: Denmark and Sweden
Participants 93 patients undergoing dental surgery
• Topical TXA group (n=44); M/F=25/19; mean age (sd)=69.8 (7.9)
• Control group (n=45); M/F=28/17; mean age (sd)=67.1 (10.5)
Interventions • Topical TXA group: After surgery but before suturing irrigated with 10ml TXA.
Patients given 27 containers of 10ml TXA and instructed to use as mouthwash for 2
minutes, 4 times a day for 7 days
• Control group: placebo (saline)
Outcomes Haematology and coagulation variables
Notes “Seven patients participated in the study two or three times.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk “..use of consecutively numbered medica-
tion packages. A written patient informa-
tion sheet and a sealed envelope with infor-
mation about the randomisation code for
each patient, to be open in case of emer-
gency, were prepared by Kabi Pharmacia
(Uppsala, Sweden).”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial described as double-blind
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Ramstrom 1993 (Continued)
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Unclear risk No data on this outcome reported
Blinding of outcome assessment (detection
bias)
Death
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Blood loss
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Thromboembolic events
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Death
Unclear risk No data on this outcome reported
Selective reporting (reporting bias) Unclear risk Insufficient information reported to permit
judgement
Roy 2012
Methods Randomised placebo-controlled trial
Setting: India
Participants 50 patients undergoing knee arthroplasty
• Topical TXA group (n=25); M/F=10/15; mean age (sd)=66.04 (7.15)
• Control group (n=25); M/F=9/16; mean age (sd)=66.56 (8.03)
Interventions • Topical TXA group: 500mg/5ml administered intra-articularly through drain
tube immediately after wound closure
• Control group: placebo (saline)
Outcomes Blood loss
Blood transfusion
Thromboembolic events
Haematology variables
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Roy 2012 (Continued)
Random sequence generation (selection
bias)
Low risk “A random number table was utilized
to generate the simple randomization se-
quence.”
Allocation concealment (selection bias) Low risk “The tranexamic acid and control solu-
tion (both colourless) were prepared and
provided in identical disposable syringes
tagged with number codes for allocation
concealment and blinding by an indepen-
dent hospital pharmacist.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
Death
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Blood loss
Low risk No exclusions reported
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Low risk No exclusions reported
Incomplete outcome data (attrition bias)
Thromboembolic events
Low risk No exclusions reported
Incomplete outcome data (attrition bias)
Death
Unclear risk No data on this outcome reported
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Sa-Ngasoongsong 2011
Methods Randomised placebo-controlled trial
Setting: Thailand
Participants 48 patients undergoing knee arthroplasty
• Topical TXA group (n=24); M/F=2/22; mean age (sd)=69.0 (8.2)
• Control group (n=24); M/F=6/18; mean age (sd)=69.2 (7.6)
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Sa-Ngasoongsong 2011 (Continued)
Interventions • Topical TXA group: 25ml (250mg of TXA in 5ml volume and 20ml of saline)
solution injected into knee joint after completion of fascial closure
• Control group: placebo (saline)
Outcomes Blood loss
Blood transfusion
Deep vein thrombosis
Functional outcome
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence
Allocation concealment (selection bias) Low risk Sequentially numbered, sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Triple-blinded trial (patient, surgeon and
outcome assessor)
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Low risk Triple-blinded trial (patient, surgeon and
outcome assessor)
Blinding of outcome assessment (detection
bias)
Death
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Blood loss
Low risk No exclusions or dropouts
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Low risk No exclusions or dropouts
Incomplete outcome data (attrition bias)
Thromboembolic events
Low risk No exclusions or dropouts
Incomplete outcome data (attrition bias)
Death
Unclear risk No data on this outcome reported
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
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Saberi 2010
Methods Randomised placebo-controlled trial
Setting: Iran
Participants 100 patients undergoing spinal surgery
• Topical TXA group (n=50); M/F=21/29; mean age (sd)=42.78 (11.52)
• Control group (n=50); M/F=18/32; mean age (sd)=39.70 (8.46)
Interventions • Topical TXA group: 250mg in 5ml solution poured into the surgical site ar the
end of the operation, left for 5 minutes before surgical closure
• Control group: placebo (saline)
Outcomes Blood loss
Length of hospital stay
Blood transfusion
Side effects
Notes Article in Persian
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
Death
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Blood loss
Low risk No exclusions
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Low risk No exclusions
Incomplete outcome data (attrition bias)
Thromboembolic events
Unclear risk No data on this outcome reported
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Saberi 2010 (Continued)
Incomplete outcome data (attrition bias)
Death
Unclear risk No data on this outcome reported
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Seo 2012
Methods Randomised placebo-controlled trial
Setting: South Korea
Participants 150* patients undergoing knee arthroplasty
• Topical TXA group (n=50); M/F=5/45; mean age (sd)=67.5 (6.6)
• Control group (n=50); M/F=5/45; mean age (sd)=67.8 (6.1)
[*third group of 50 patients received intravenous TXA, not included in this review]
Interventions • Topical TXA group: 1.5g in 100cc saline injected into the knee joint cavity while
suturing
• Control group: placebo (saline)
Outcomes Blood loss
Blood transfusion
Deep vein thrombosis, pulmonary embolism
Death
Haemoglobin level
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “..using a random numbers list.”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Unclear risk Not described
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Seo 2012 (Continued)
Blinding of outcome assessment (detection
bias)
Death
Low risk Not described, however judged that the
outcome measurement was unlikely to be
influenced by lack of blinding
Incomplete outcome data (attrition bias)
Blood loss
Low risk No exclusions
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Low risk No exclusions
Incomplete outcome data (attrition bias)
Thromboembolic events
Low risk No exclusions
Incomplete outcome data (attrition bias)
Death
Low risk No exclusions
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Sindet-Pedersen 1989
Methods Randomised placebo-controlled trial
Setting: Denmark and Sweden
Participants 45* patients undergoing oral surgery
• Topical TXA group (n=19); M/F=11/8; mean age=55.65
• Control group (n=20); M/F=11/9; mean age=57.91
[*6 patients excluded after randomisation]
Interventions • Topical TXA group: before suturing, the operative field was irrigated with 10ml
of 4.8% solution of TXA. Patients instructed to rinse mouths with 10ml of solution for
2 minutes, 4 times a day for 7 days
• Control group: placebo
Outcomes Bleeding episodes
Haematology and coagulation variables
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomnumberswere used to assign con-
secutive patients to treatment groups.”
Allocation concealment (selection bias) Unclear risk Not described
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Sindet-Pedersen 1989 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial described as double-blind
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Unclear risk No data on this outcome reported
Blinding of outcome assessment (detection
bias)
Death
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Blood loss
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Thromboembolic events
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Death
Unclear risk No data on this outcome reported
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Tibbelin 1995
Methods Randomised placebo-controlled trial
Setting: Sweden
Participants 68 patients with epistaxis
• Topical TXA group (n=30); M/F=21/14; mean age (range)=50 (23-89)
• Control group (n=38); M/F=28/10; mean age (range)=65 (21-88)
Interventions • Topical TXA group: gel (15ml) containing 10% TXA applied to the nasal cavity
• Control group: placebo gel
Outcomes Re-bleeding
Patients’ acceptance of treatment
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Tibbelin 1995 (Continued)
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Unclear risk No data on this outcome reported
Blinding of outcome assessment (detection
bias)
Death
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Blood loss
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Thromboembolic events
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Death
Unclear risk No data on this outcome reported
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Van Elst 2013
Methods Randomised placebo-controlled trial
Setting: Belgium
Participants 67 patients undergoing hip arthroplasty
• Topical TXA group 1 (n=22); M/F=NR; mean age=NR
• Topical TXA group 2 (n=19); M/F=NR; mean age=NR
• Control group (n=26); M/F=NR; mean age=NR
Interventions • Topical TXA group 1: 3g TXA administered intra-articularly 15 minutes before
opening of the drain
• Topical TXA group 2: 3g TXA administered intra-articularly 2 hours before
opening of the drain
• Control group: placebo
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Van Elst 2013 (Continued)
Outcomes Blood loss (estimated)
Thromboembolic events
Transfusion need
Post-operative swelling and pain
Length of hospital stay
Notes Conference abstract
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported
Allocation concealment (selection bias) Unclear risk No information reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Low risk Described as double-blind
Blinding of outcome assessment (detection
bias)
Death
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Blood loss
Low risk No exclusions reported
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Thromboembolic events
Low risk No exclusions reported
Incomplete outcome data (attrition bias)
Death
Unclear risk No data on this outcome reported
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
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Wong 2010
Methods Randomised placebo-controlled trial
Setting: Canada
Participants 124 patients undergoing total knee arthroplasty
• Topical TXA group 1 (n=44): M/F=6/25; mean age (sd)=67 (11.9)
• Topical TXA group 2 (n=40): M/F=14/19; mean age (sd)=63.9 (10.6)
• Control group (n=40): M/F=13/22; mean age (sd)=68.4 (10.4)
Interventions • Topical TXA group 1: 1.5g TXA in 100ml saline, left in place for 5 minutes
• Topical TXA group 2: 3g TXA in 100ml saline, in place for 5 minutes
• Control group: placebo
Outcomes Blood loss (estimated)
Receipt of blood transfusion
Thromboembolic events
Surgical infections
Length of hospital stay
Joint function
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Sequentially numbered, opaque sealed en-
velopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The patients, surgeons, anaesthesiologists,
health-care providers, research personnel,
and outcome assessors were blinded to the
randomization.”
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Low risk “The patients, surgeons, anaesthesiologists,
health-care providers, research personnel,
and outcome assessors were blinded to the
randomization.”
Blinding of outcome assessment (detection
bias)
Death
Low risk “The patients, surgeons, anaesthesiologists,
health-care providers, research personnel,
and outcome assessors were blinded to the
randomization.”
Incomplete outcome data (attrition bias)
Blood loss
Unclear risk Blood loss was estimated from difference
between pre and post operative haemoglo-
bin level and not included in meta-analysis
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Wong 2010 (Continued)
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
High risk 18patientswhodidnot receive the assigned
intervention were excluded after randomi-
sation (13 from topical TXA group 1, 6
from topical TXA group 2, and 5 from the
control group
Incomplete outcome data (attrition bias)
Thromboembolic events
High risk 18patientswhodidnot receive the assigned
intervention were excluded after randomi-
sation (13 from topical TXA group 1, 6
from topical TXA group 2, and 5 from the
control group
Incomplete outcome data (attrition bias)
Death
High risk 18patientswhodidnot receive the assigned
intervention were excluded after randomi-
sation (13 from topical TXA group 1, 6
from topical TXA group 2, and 5 from the
control group
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Yasim 2005
Methods Randomised placebo-controlled trial
Setting: Turkey
Participants 30* patients undergoing total knee arthroplasty
• Topical TXA group (n=10): M/F=6/4; mean age (sd)=50.5 (14.3)
• Control group (n=10): M/F=5/5; mean age (sd)=51.7 (10.4)
[*third group of 10 patients received aprotinin, not included in this review]
Interventions • Topical TXA group: 1g of TXA in 100ml saline poured into pericardial space
• Control group: placebo (saline)
Outcomes Blood loss
Amount of blood transfused
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
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Yasim 2005 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
Blood loss, receipt of blood transfusion,
thromboembolic events
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
Death
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Blood loss
Low risk No exclusions reported
Incomplete outcome data (attrition bias)
Receipt of blood transfusion
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Thromboembolic events
Unclear risk No data on this outcome reported
Incomplete outcome data (attrition bias)
Death
Unclear risk No data on this outcome reported
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bernardoni-Socorro 1998 Not randomised
Borea 1993 Intervention also included variation in level of anti-coagulant treatment
Carter 2003 Both groups received TXA
Falbe-Hansen 1974 Unable to determine if allocation was random
Hegde 2013 Not randomised
Maniar 2012 All groups received TXA
Mutsuzaki 2012 Not randomised
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(Continued)
Timocin 1996 Not randomised
Characteristics of ongoing studies [ordered by study ID]
NCT01260818
Trial name or title Prospective Randomized Trial Comparing Topical Tranexamic Acid Plus Standard Of Care Versus Standard
Of Care For The Reduction Of Blood Loss Following Primary Total Hip Arthroplasty Surgery
Methods Randomised, single-blind, placebo-controlled trial. Planned sample size=100
Participants Patients aged 18-90 years undergoing total hip arthroplasty
Interventions 1g TXA in 100ml saline administered to wound 2 hours before drainage is opened
Outcomes Blood loss
Haemoglobin levels
No. of patients receiving transfusion
Starting date December 2010
Contact information Yong Li, First Affiliated Hospital of Guangzhou TCM University (liyong1949@gmail.com)
Notes
NCT01519245
Trial name or title Topical Application of Tranexamic Acid to Reduce Post-operative Bleeding inCoronary Artery Bypass Surgery
Methods Randomised, double-blind, placebo-controlled trial. Planned sample size=44
Participants Patients aged 18 years and over undergoing elective or urgent coronary artery bypass surgery
Interventions 2g TXA in 50ml of saline poured over the heart prior to sternotomy closure
Outcomes Blood loss
No. of transfusions
Starting date December 2011
Contact information Kelsey Brose MD, Division of haematology, University of Saskatchewan
Notes
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NCT01683955
Trial name or title Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty
Methods Randomised, double-blind, placebo-controlled trial. Planned sample size=101
Participants Patients aged 18 years and over undergoing total hip arthroplasty
Interventions 2g TXA in 100ml applied during surgery
Outcomes Blood loss
Transfusion rate
No. units transfused
Starting date June 2011
Contact information Michael Laker MD, Henry Ford Health Systems
Notes
NCT01727843
Trial name or title Phase III Examining the Topical Application of Tranexamic Acid and Postoperative Blood Loss in Femoral
Neck Fractures: a Randomized Control Trial
Methods Randomised, double-blind, placebo-controlled trial. Planned sample size=126
Participants Patients aged 65-95 years undergoing surgery for femoral neck fracture repair
Interventions 3g TXA applied directly to the wound at the end of the procedure
Outcomes Blood loss
Starting date April 2013
Contact information granth@queensu.ca
Notes
TRANX-H
Trial name or title Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replace-
ment: a randomised controlled trial (TRANX-H)
Methods Randomised, double-blind, placebo-controlled trial. Planned sample size=158
Participants Patients undergoing primary total hip replacement
Interventions TXA sprayed topically into the exposed tissue around the hip joint prior to wound closure
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TRANX-H (Continued)
Outcomes Blood transfusion
Blood loss
Haemoglobin and haematocrit
Quality of life
Length of stay
Starting date August 2009
Contact information Antoni Nargol, the North Tees & Hartlepool University Hospital, UK
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Topical tranexamic acid versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood loss 18 1651 Ratio (Fixed, 95% CI) 0.71 [0.69, 0.72]
1.1 Cardiac surgery 7 511 Ratio (Fixed, 95% CI) 0.63 [0.61, 0.66]
1.2 Knee arthroplasty 5 427 Ratio (Fixed, 95% CI) 0.57 [0.53, 0.62]
1.3 Orthognathic surgery 1 40 Ratio (Fixed, 95% CI) 0.93 [0.73, 1.20]
1.4 Otolaryngological surgery 2 456 Ratio (Fixed, 95% CI) 0.74 [0.73, 0.76]
1.5 Spinal surgery 2 130 Ratio (Fixed, 95% CI) 0.50 [0.43, 0.58]
1.6 Thoracic surgery 1 87 Ratio (Fixed, 95% CI) 0.95 [0.86, 1.05]
2 Estimated blood loss Other data No numeric data
3 Mortality 9 894 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.06, 1.34]
4 Myocardial infarction 6 362 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.04, 3.08]
5 Stroke 5 441 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.96]
6 Deep vein thrombosis 9 789 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.31, 1.57]
7 Pulmonary embolism 8 741 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.09, 3.15]
8 Blood transfusion 15 1623 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.46, 0.65]
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Analysis 1.1. Comparison 1 Topical tranexamic acid versus control, Outcome 1 Blood loss.
Review: Topical application of tranexamic acid for the reduction of bleeding
Comparison: 1 Topical tranexamic acid versus control
Outcome: 1 Blood loss
Study or subgroup Topical TXA Control log [Ratio] Ratio Weight Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Cardiac surgery
Baric 2007 97 96 -0.231 (0.089) 1.3 % 0.79 [ 0.67, 0.95 ]
Fawzy 2009 19 19 -0.351 (0.188) 0.3 % 0.70 [ 0.49, 1.02 ]
Kurt 2011 20 20 -0.435 (0.117) 0.7 % 0.65 [ 0.51, 0.81 ]
Nouraei 2013 40 40 -0.356 (0.119) 0.7 % 0.70 [ 0.55, 0.88 ]
De Bonis 2000 20 20 -0.248 (0.092) 1.2 % 0.78 [ 0.65, 0.93 ]
Abul-Azm 2006 50 50 -0.503 (0.023) 18.9 % 0.60 [ 0.58, 0.63 ]
Yasim 2005 10 10 -0.02 (0.193) 0.3 % 0.98 [ 0.67, 1.43 ]
Subtotal (95% CI) 256 255 23.3 % 0.63 [ 0.61, 0.66 ]
Heterogeneity: Chi2 = 21.76, df = 6 (P = 0.001); I2 =72%
Test for overall effect: Z = 22.29 (P < 0.00001)
2 Knee arthroplasty
Roy 2012 25 25 -0.769 (0.061) 2.7 % 0.46 [ 0.41, 0.52 ]
Sa-Ngasoongsong 2011 24 24 -0.621 (0.137) 0.5 % 0.54 [ 0.41, 0.70 ]
Alshryda 2013 64 65 -0.457 (0.105) 0.9 % 0.63 [ 0.52, 0.78 ]
Seo 2012 50 50 -0.658 (0.658) 0.0 % 0.52 [ 0.14, 1.88 ]
Ishida 2011 50 50 -0.166 (0.086) 1.4 % 0.85 [ 0.72, 1.00 ]
Subtotal (95% CI) 213 214 5.5 % 0.57 [ 0.53, 0.62 ]
Heterogeneity: Chi2 = 33.89, df = 4 (P<0.00001); I2 =88%
Test for overall effect: Z = 13.01 (P < 0.00001)
3 Orthognathic surgery
Kaewpradub 2011 20 20 -0.068 (0.128) 0.6 % 0.93 [ 0.73, 1.20 ]
Subtotal (95% CI) 20 20 0.6 % 0.93 [ 0.73, 1.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
4 Otolaryngological surgery
Jabalameli 2006 26 30 -0.272 (0.022) 20.6 % 0.76 [ 0.73, 0.80 ]
Albirmawy 2013 200 200 -0.309 (0.015) 44.4 % 0.73 [ 0.71, 0.76 ]
Subtotal (95% CI) 226 230 65.0 % 0.74 [ 0.73, 0.76 ]
Heterogeneity: Chi2 = 1.93, df = 1 (P = 0.16); I2 =48%
0.5 0.7 1 1.5 2
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(Continued . . . )
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(. . . Continued)
Study or subgroup Topical TXA Control log [Ratio] Ratio Weight Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Test for overall effect: Z = 23.99 (P < 0.00001)
5 Spinal surgery
Krohn 2002 16 14 -0.81 (0.203) 0.2 % 0.44 [ 0.30, 0.66 ]
Saberi 2010 50 50 -0.674 (0.078) 1.6 % 0.51 [ 0.44, 0.59 ]
Subtotal (95% CI) 66 64 1.9 % 0.50 [ 0.43, 0.58 ]
Heterogeneity: Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 9.50 (P < 0.00001)
6 Thoracic surgery
Dell’Amore 2012 44 43 -0.049 (0.052) 3.7 % 0.95 [ 0.86, 1.05 ]
Subtotal (95% CI) 44 43 3.7 % 0.95 [ 0.86, 1.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
Total (95% CI) 825 826 100.0 % 0.71 [ 0.69, 0.72 ]
Heterogeneity: Chi2 = 188.32, df = 17 (P<0.00001); I2 =91%
Test for overall effect: Z = 34.67 (P < 0.00001)
Test for subgroup differences: Chi2 = 130.34, df = 5 (P = 0.00), I2 =96%
0.5 0.7 1 1.5 2
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Analysis 1.2. Comparison 1 Topical tranexamic acid versus control, Outcome 2 Estimated blood loss.
Estimated blood loss
Study Blood loss (ml) in topical
TXA gp (mean, sd)
Blood loss (ml) in con-
trol gp (mean, sd)
Mean difference (95%
CI)
Test for effect (P value)
Alshryda 2013 297(196); n=64 465(298); n=65 -168.00 (-254.91 to -81.
09)
0.0002
Georgiadis 2013 940.2(327.1); n=50 1293.1(532.7); n=51 -352.90 (-524.93 to 180.
87)
<0.0001
Wong 2010 1g: 1295(349); n=31
3g: 1208(367); n=33
1610(378); n=35 -315.00 (-490.43 to -139.
57)
-402.00 (-579.09 to -224.
91)
0.0004
<0.0001
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Analysis 1.3. Comparison 1 Topical tranexamic acid versus control, Outcome 3 Mortality.
Review: Topical application of tranexamic acid for the reduction of bleeding
Comparison: 1 Topical tranexamic acid versus control
Outcome: 3 Mortality
Study or subgroup Topical TXA Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abul-Azm 2006 1/50 4/50 57.0 % 0.25 [ 0.03, 2.16 ]
Alshryda 2013 0/79 0/78 Not estimable
Baric 2007 1/97 3/96 43.0 % 0.33 [ 0.03, 3.12 ]
De Bonis 2000 0/20 0/20 Not estimable
Dell’Amore 2012 0/44 0/43 Not estimable
Fawzy 2009 0/19 0/19 Not estimable
Nouraei 2013 0/40 0/40 Not estimable
Seo 2012 0/50 0/50 Not estimable
Wong 2010 0/64 0/35 Not estimable
Total (95% CI) 463 431 100.0 % 0.28 [ 0.06, 1.34 ]
Total events: 2 (Topical TXA), 7 (Control)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
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Analysis 1.4. Comparison 1 Topical tranexamic acid versus control, Outcome 4 Myocardial infarction.
Review: Topical application of tranexamic acid for the reduction of bleeding
Comparison: 1 Topical tranexamic acid versus control
Outcome: 4 Myocardial infarction
Study or subgroup Topical TXA Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Bonis 2000 0/20 1/20 49.7 % 0.33 [ 0.01, 7.72 ]
Dell’Amore 2012 0/44 1/43 50.3 % 0.33 [ 0.01, 7.79 ]
Fawzy 2009 0/19 0/19 Not estimable
Nouraei 2013 0/40 0/40 Not estimable
Roy 2012 0/25 0/25 Not estimable
Van Elst 2013 0/41 0/26 Not estimable
Total (95% CI) 189 173 100.0 % 0.33 [ 0.04, 3.08 ]
Total events: 0 (Topical TXA), 2 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours topical TXA Favours control
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Analysis 1.5. Comparison 1 Topical tranexamic acid versus control, Outcome 5 Stroke.
Review: Topical application of tranexamic acid for the reduction of bleeding
Comparison: 1 Topical tranexamic acid versus control
Outcome: 5 Stroke
Study or subgroup Topical TXA Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alshryda 2013 0/79 1/78 100.0 % 0.33 [ 0.01, 7.96 ]
Dell’Amore 2012 0/44 0/43 Not estimable
Nouraei 2013 0/40 0/40 Not estimable
Roy 2012 0/25 0/25 Not estimable
Van Elst 2013 0/41 0/26 Not estimable
Total (95% CI) 229 212 100.0 % 0.33 [ 0.01, 7.96 ]
Total events: 0 (Topical TXA), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
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Analysis 1.6. Comparison 1 Topical tranexamic acid versus control, Outcome 6 Deep vein thrombosis.
Review: Topical application of tranexamic acid for the reduction of bleeding
Comparison: 1 Topical tranexamic acid versus control
Outcome: 6 Deep vein thrombosis
Study or subgroup Topical TXA Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alshryda 2013 2/79 0/78 3.8 % 4.94 [ 0.24, 101.22 ]
Dell’Amore 2012 0/44 0/43 Not estimable
Georgiadis 2013 4/50 9/51 67.5 % 0.45 [ 0.15, 1.38 ]
Nouraei 2013 0/40 0/40 Not estimable
Roy 2012 0/25 0/25 Not estimable
Sa-Ngasoongsong 2011 0/24 0/24 Not estimable
Seo 2012 0/50 2/50 18.9 % 0.20 [ 0.01, 4.06 ]
Van Elst 2013 0/41 0/26 Not estimable
Wong 2010 3/64 1/35 9.8 % 1.64 [ 0.18, 15.19 ]
Total (95% CI) 417 372 100.0 % 0.69 [ 0.31, 1.57 ]
Total events: 9 (Topical TXA), 12 (Control)
Heterogeneity: Chi2 = 3.41, df = 3 (P = 0.33); I2 =12%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.7. Comparison 1 Topical tranexamic acid versus control, Outcome 7 Pulmonary embolism.
Review: Topical application of tranexamic acid for the reduction of bleeding
Comparison: 1 Topical tranexamic acid versus control
Outcome: 7 Pulmonary embolism
Study or subgroup Topical TXA Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Georgiadis 2013 1/50 2/51 60.5 % 0.51 [ 0.05, 5.45 ]
Wong 2010 1/64 1/35 39.5 % 0.55 [ 0.04, 8.48 ]
Roy 2012 0/25 0/25 Not estimable
Alshryda 2013 0/79 0/78 Not estimable
Dell’Amore 2012 0/44 0/43 Not estimable
Nouraei 2013 0/40 0/40 Not estimable
Van Elst 2013 0/41 0/26 Not estimable
Seo 2012 0/50 0/50 Not estimable
Total (95% CI) 393 348 100.0 % 0.52 [ 0.09, 3.15 ]
Total events: 2 (Topical TXA), 3 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
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Analysis 1.8. Comparison 1 Topical tranexamic acid versus control, Outcome 8 Blood transfusion.
Review: Topical application of tranexamic acid for the reduction of bleeding
Comparison: 1 Topical tranexamic acid versus control
Outcome: 8 Blood transfusion
Study or subgroup Topical TXA Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wong 2010 5/64 9/35 5.7 % 0.30 [ 0.11, 0.84 ]
Baric 2007 51/97 51/96 25.1 % 0.99 [ 0.76, 1.29 ]
Alshryda 2013 1/79 13/78 6.4 % 0.08 [ 0.01, 0.57 ]
Sa-Ngasoongsong 2011 1/24 8/24 3.9 % 0.13 [ 0.02, 0.92 ]
Roy 2012 2/25 7/25 3.4 % 0.29 [ 0.07, 1.24 ]
Georgiadis 2013 0/50 4/51 2.2 % 0.11 [ 0.01, 2.05 ]
Fawzy 2009 14/19 13/19 6.4 % 1.08 [ 0.72, 1.62 ]
Albirmawy 2013 0/200 2/200 1.2 % 0.20 [ 0.01, 4.14 ]
Nouraei 2013 15/40 21/40 10.3 % 0.71 [ 0.43, 1.17 ]
De Bonis 2000 3/20 4/20 2.0 % 0.75 [ 0.19, 2.93 ]
Seo 2012 10/50 47/50 23.0 % 0.21 [ 0.12, 0.37 ]
Saberi 2010 0/50 0/50 Not estimable
Krohn 2002 2/16 9/14 4.7 % 0.19 [ 0.05, 0.75 ]
Dell’Amore 2012 8/44 10/43 5.0 % 0.78 [ 0.34, 1.79 ]
Ishida 2011 0/50 1/50 0.7 % 0.33 [ 0.01, 7.99 ]
Total (95% CI) 828 795 100.0 % 0.55 [ 0.46, 0.65 ]
Total events: 112 (Topical TXA), 199 (Control)
Heterogeneity: Chi2 = 54.48, df = 13 (P<0.00001); I2 =76%
Test for overall effect: Z = 6.55 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours topical TXA Favours control
67Topical application of tranexamic acid for the reduction of bleeding (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A P P E N D I C E S
Appendix 1. Search strategies
Cochrane Injuries Group Specialised Register
(tranexamic or “Cyclohexanecarboxylic Acid*” or Methylamine* or amcha or “trans-4-aminomethyl-cyclohexanecarboxylic acid*” or t-
amcha or amca or “kabi 2161” or transamin* or exacyl or amchafibrin or anvitoff or spotof or cyklokapron or “ugurol oramino methyl-
cyclohexane carboxylate” or “aminomethylcyclohexanecarbonic acid” or “aminomethylcyclohexanecarboxylic acid” or AMCHA or am-
chafibrin or amikapron or “aminomethyl cyclohexane carboxylic acid” or “aminomethyl cyclohexanecarboxylic acid” or “aminomethyl-
cyclohexane carbonic acid” or “aminomethylcyclohexane carboxylic acid” or “aminomethylcyclohexanecarbonic acid” or “aminomethyl-
cyclohexanecarboxylic acid” or “aminomethylcyclohexanocarboxylic acid” or “aminomethylcyclohexanoic acid” or amstat or anvitoff
or cl?65336 or cl65336 or cyclocapron or cyclokapron or cyklocapron or exacyl or frenolyse or hexacapron or hexakapron or tranex or
TXA) AND (topical* or intra-articular* or intraarticular* or irrigat* or mouthwash* or rins* or intra-nasal* or intranasal* or rectal* or
intra-vaginal* or intravaginal* or spray*)
Cochrane Central Register of Controlled Trials (The Cochrane Library)
#1MeSH descriptor: [Antifibrinolytic Agents] explode all trees
#2MeSH descriptor: [Tranexamic Acid] explode all trees
#3(anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or anti-fibrinolysin* or antiplasmin* or anti-plasmin*):ti,ab,kw (Word
variations have been searched)
#4(plasmin or fibrinolysis) near/3 (inhibitor*):ti,ab,kw (Word variations have been searched)
#5#3 or #4
#6(tranexamic or Cyclohexanecarboxylic Acid* or Methylamine* or amcha or trans-4-aminomethyl-cyclohexanecarboxylic acid* or t-
amcha or amca or kabi 2161 or transamin* or exacyl or amchafibrin or anvitoff or spotof or cyklokapron or ugurol oramino methylcyclo-
hexane carboxylate or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or AMCHA or amchafibrin
or amikapron or aminomethyl cyclohexane carboxylic acid or aminomethyl cyclohexanecarboxylic acid or aminomethylcyclohexane
carbonic acid or aminomethylcyclohexane carboxylic acid or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecar-
boxylic acid or aminomethylcyclohexanocarboxylic acid or aminomethylcyclohexanoic acid or amstat or anvitoff or cl?65336 or cl65336
or cyclocapron or cyclokapron or cyklocapron or exacyl or frenolyse or hexacapron or hexakapron or tranex or TXA):ti,ab,kw (Word
variations have been searched)
#7#1 or #2 or #5 or #6
#8MeSH descriptor: [Administration, Topical] explode all trees
#9topical* or intra-articular* or intraarticular* or (local* near/3 appl*) or irrigat* or mouthwash* or rins* or intra-nasal* or intranasal*
or rectal* or intra-vaginal* or intravaginal* or spray*:ti,ab,kw (Word variations have been searched)
#10#8 or #9
#11#7 and #10
Ovid MEDLINE(R), Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid
OLDMEDLINE(R)
1. exp Antifibrinolytic Agents/
2. (anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or anti-fibrinolysin* or antiplasmin* or anti-plasmin* or ((plasmin or
fibrinolysis) adj3 inhibitor*)).ab,ti.
3. exp Tranexamic Acid/
4. (tranexamic or Cyclohexanecarboxylic Acid* or Methylamine* or trans-4-aminomethyl-cyclohexanecarboxylic acid* or t-amcha or
amca or kabi 2161 or transamin* or exacyl or amchafibrin or spotof or cyklokapron or ugurol oramino methylcyclohexane carboxy-
late or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or AMCHA or amchafibrin or amikapron
or aminomethyl cyclohexane carboxylic acid or aminomethyl cyclohexanecarboxylic acid or aminomethylcyclohexane carbonic acid
or aminomethylcyclohexane carboxylic acid or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or
aminomethylcyclohexanocarboxylic acid or aminomethylcyclohexanoic acid or amstat or anvitoff or cl?65336 or cl65336 or cyclo-
capron or cyclokapron or cyklocapron or exacyl or frenolyse or hexacapron or hexakapron or tranex or TXA).ab,ti.
5. 1 or 2 or 3 or 4
6. exp Administration, Topical/
7. (topical* or intra-articular* or intraarticular* or (local* adj3 appl*) or irrigat* or mouthwash* or rins* or intra-nasal* or intranasal*
or rectal* or intra-vaginal* or intravaginal* or spray*).ab,ti.
8. 6 or 7
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9. 5 and 8
10. randomi?ed.ab,ti.
11. randomized controlled trial.pt.
12. controlled clinical trial.pt.
13. placebo.ab.
14. clinical trials as topic.sh.
15. randomly.ab.
16. trial.ti.
17. Comparative Study/
18. exp clinical trial/
19. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
20. (animals not (humans and animals)).sh.
21. 19 not 20
22. 9 and 21
Embase Classic + Embase
1. exp Antifibrinolytic Agents/
2. (anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or anti-fibrinolysin* or antiplasmin* or anti-plasmin* or ((plasmin or
fibrinolysis) adj3 inhibitor*)).ab,ti.
3. exp Tranexamic Acid/
4. (tranexamic or Cyclohexanecarboxylic Acid* or Methylamine* or amcha or trans-4-aminomethyl-cyclohexanecarboxylic acid* or t-
amcha or amca or kabi 2161 or transamin* or exacyl or amchafibrin or anvitoff or spotof or cyklokapron or ugurol oramino methylcyclo-
hexane carboxylate or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or AMCHA or amchafibrin
or amikapron or aminomethyl cyclohexane carboxylic acid or aminomethyl cyclohexanecarboxylic acid or aminomethylcyclohexane
carbonic acid or aminomethylcyclohexane carboxylic acid or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecar-
boxylic acid or aminomethylcyclohexanocarboxylic acid or aminomethylcyclohexanoic acid or amstat or anvitoff or cl?65336 or cl65336
or cyclocapron or cyclokapron or cyklocapron or exacyl or frenolyse or hexacapron or hexakapron or tranex or TXA).ab,ti.
5. 1 or 2 or 3 or 4
6. exp Administration, Topical/
7. (topical* or intra-articular* or intraarticular* or (local* adj3 appl*) or irrigat* or mouthwash* or rins* or intra-nasal* or intranasal*
or rectal* or intra-vaginal* or intravaginal* or spray*).ti,ab.
8. 6 or 7
9. 5 and 8
10. exp Randomized Controlled Trial/
11. exp controlled clinical trial/
12. exp controlled study/
13. comparative study/
14. randomi?ed.ab,ti.
15. placebo.ab.
16. *Clinical Trial/
17. exp major clinical study/
18. randomly.ab.
19. (trial or study).ti.
20. 10 or 11 or 12 or 14 or 15 or 16 or 17 or 18 or 19
21. exp animal/ not (exp human/ and exp animal/)
22. 20 not 21
23. 9 and 22
24. limit 23 to embase
ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED)
ISI Web of Science: Conference Proceedings Citation Index-Science (CPCI-S)
#16 #15 AND #11 AND #6
#15 #14 OR #13 OR #12
#14 TS=(local* near/3 appl*)
#13 TS=(irrigat* or mouthwash* or rins* or intra-nasal* or intranasal* or rectal* or intra-vaginal* or intravaginal* or spray*)
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#12 TS= (topical* OR intra-articular* OR intraarticular*)
#11 #10 OR #9 OR #8 OR #7
#10 TS=(AMCHA or amchafibrin or amikapron or ’aminomethyl cyclohexane carboxylic acid’ or ’aminomethyl cyclohexanecarboxylic
acid’ or ’aminomethylcyclohexane carbonic acid’ or ’aminomethylcyclohexane carboxylic acid’ or ’aminomethylcyclohexanecarbonic
acid’ or ’aminomethylcyclohexanecarboxylic acid’ or ’aminomethylcyclohexanocarboxylic acid’ or ’aminomethylcyclohexanoic acid’
or amstat or anvitoff or cl-65336 or cl65336 or cyclocapron or cyclokapron or cyklocapron or exacyl or frenolyse or hexacapron or
hexakapron or tranex or TXA)
#9 TS=(tranexamic or ’Cyclohexanecarboxylic Acid*’ or Methylamine* or amcha or trans-4-aminomethyl-cyclohexanecarboxylic acid*
or t-amcha or amca or ’kabi 2161’ or transamin* or exacyl or amchafibrin or anvitoff or spotof or cyklokapron or ’ugurol oramino
methylcyclohexane carboxylate’ or ’aminomethylcyclohexanecarbonic acid’ or ’aminomethylcyclohexanecarboxylic acid’)
#8 TS=(((plasmin or fibrinolysis) n3 inhibitor*))
#7 TS=(anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or anti-fibrinolysin* or antiplasmin* or anti-plasmin*)
#6 #5 AND #4
#5 TS=(human*)
#4 #3 OR #2 OR #1
#3 TS=((singl* OR doubl* OR trebl* OR tripl*) SAME (blind* OR mask*))
#2 TS=(controlled clinical trial OR controlled trial OR clinical trial OR placebo)
#1 TS=(randomised OR randomized OR randomly OR random order OR random sequence OR random allocation OR randomly
allocated OR at random OR randomized controlled trial)
PubMed
((((((((((“Comparative Study”[Publication Type]) OR “Randomized Controlled Trial”[Publication Type]) OR “Controlled Clinical
Trial”[Publication Type])) OR (((((((randomized[Title/Abstract]) OR randomised[Title/Abstract]) OR placebo[Title/Abstract]) OR
randomly[Title/Abstract])OR trial[Title/Abstract])OR study[Title/Abstract])ORgroup*[Title/Abstract])))NOT ((“Animals”[Mesh])
NOT (“Animals”[Mesh] AND “Humans”[Mesh])))) AND ((((((((local[Title/Abstract]) AND application[Title/Abstract])) OR (“lo-
cal application”[title/abstract])) OR (topical*[title/abstract] OR intra-articular*[title/abstract] OR intraarticular*[title/abstract] OR
irrigat*[title/abstract] OR mouthwash*[title/abstract] OR rins*[title/abstract] OR intra-nasal*[title/abstract] OR intranasal*[title/
abstract] OR rectal*[title/abstract] OR intra-vaginal*[title/abstract] OR intravaginal*[title/abstract] OR spray*[title/abstract])) OR
(“Administration, Topical”[Mesh]))) AND ((((((“Antifibrinolytic Agents”[Mesh]) OR “Tranexamic Acid”[Mesh])) OR (anti-fibri-
nolytic*[title/abstract] OR antifibrinolytic*[title/abstract] OR antifibrinolysin*[title/abstract] OR anti-fibrinolysin*[title/abstract] OR
antiplasmin*[title/abstract] OR anti-plasmin*[title/abstract])) OR (((inhibitor[title/abstract])) AND (plasmin[title] OR fibrinoly-
sis[title/abstract]))) OR (tranexamic[title/abstract] OR “Cyclohexanecarboxylic Acid*”[title/abstract] ORMethylamine*[title/abstract]
OR “trans-4-aminomethyl-cyclohexanecarboxylic acid*”[title/abstract] OR t-amcha[title/abstract] OR amca[title/abstract] OR “kabi
2161”[title/abstract] OR transamin*[title/abstract] OR exacyl[title/abstract] OR amchafibrin[title/abstract] OR spotof[title/abstract]
OR cyklokapron[title/abstract] OR “ugurol oramino methylcyclohexane carboxylate”[title/abstract] OR “aminomethylcyclohexanecar-
bonic acid”[title/abstract] OR “aminomethylcyclohexanecarboxylic acid”[title/abstract] OR AMCHA[title/abstract] OR amchafib-
rin[title/abstract] OR amikapron[title/abstract] OR “aminomethyl cyclohexane carboxylic acid”[title/abstract] OR “aminomethyl cy-
clohexanecarboxylic acid”[title/abstract] OR “aminomethylcyclohexane carbonic acid”[title/abstract] OR “aminomethylcyclohexane
carboxylic acid”[title/abstract] OR “aminomethylcyclohexanecarbonic acid”[title/abstract] OR “aminomethylcyclohexanecarboxylic
acid”[title/abstract] OR “aminomethylcyclohexanocarboxylic acid”[title/abstract] OR “aminomethylcyclohexanoic acid”[title/abstract]
OR amstat[title/abstract] OR anvitoff[title/abstract] OR cl?65336[title/abstract] OR cl65336[title/abstract] OR cyclocapron[title/ab-
stract] OR cyclokapron[title/abstract] OR cyklocapron[title/abstract] OR exacyl[title/abstract] OR frenolyse[title/abstract] OR hexa-
capron[title/abstract] OR hexakapron[title/abstract] OR tranex[title/abstract] OR TXA[title/abstract]))))) NOT (MEDLINE[SB])
Clinical trials registries
(randomised or randomized) AND (antifibrinolytic or anti-fibrinolytic or “tranexamic acid”)
AND
Study design: Interventional
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